1
EXHIBIT 12.1
Axys Pharmaceuticals, Inc.
Statement re: Computation of Ratio of Earnings to Fixed Charges
(in thousands, except ratios)
December 31
-----------------------------------------------------
1995 1996 1997 1998(2) 1999 2000
----------------------------------------------------- ----------
Add:
Consolidated loss from continuing operations (23,733) (5,928) (10,967) (156,124) (48,763) (8,492)
- minority interests in consolidated subsidiaries - - - 2,393 836 (408)
- income or loss from 50% or less owned affiliates (112) (1,879) -
Interest 1,053 2,559 2,554 2,584 436 327
----------------------------------------------------- ----------
Total Earnings (22,680) (3,369) (8,413) (151,259) (49,370) (8,573)
Interest expense 990 2,470 2,422 2,317 260 284
Estimated interest within rental expense 63 89 132 267 176 43
----------------------------------------------------- ----------
Total Fixed Charges 1,053 2,559 2,554 2,584 436 327
Ratio of Earnings to Fixed Charges (1) (1) (1) (1) (1) (1)
Dollar Amount of Deficiency 23,733 5,928 10,967 153,843 49,806 8,900
- ----------
(1) Earnings (as defined) for the period were insufficient to cover fixed
charges by the amount disclosed.
(2) Includes charges to earnings resulting from acquired in-process research
and development costs.